News · 26 weeks121-25%
2025-11-022026-04-26
Mix6190d
- Other30(49%)
- Insider16(26%)
- SEC Filings6(10%)
- Earnings4(7%)
- Analyst3(5%)
- Leadership2(3%)
Latest news
25 items- SECMerck & Company Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Merck & Co., Inc. (0000310158) (Filer)
- PRMerck & Co., Inc., Rahway, N.J., USA Announces First-Quarter 2026 Financial Results; Highlights Significant Regulatory Approvals and Clinical MilestonesSales Growth Driven by Continued Strength in Oncology and Animal Health, Plus Increasing Contributions From Launches Total Worldwide Sales Were $16.3 Billion (5% Growth; 3% Growth ex-FX) KEYTRUDA/KEYTRUDA QLEX1 Sales Were $8.0 Billion (12% Growth; 8% Growth ex-FX); Includes KEYTRUDA QLEX Sales of $128 Million WINREVAIR Sales Were $525 Million (88% Growth; 87% Growth ex-FX) Animal Health Sales Were $1.8 Billion (13% Growth; 6% Growth ex-FX) GAAP Loss per Share Was $1.72; Non-GAAP Loss per Share Was $1.28; GAAP and Non-GAAP Loss per Share Include a Charge of $3.62 per Share for the Acquisition of Cidara Presented New Data From Cardio-Pulmonary Pipeline at ACC.26, Including
- PRMerck's Playing with Heart Program Teams Up With Professional Baseball Clubs and Baseball Legends to Help Raise Awareness About LDL-C, Called "Bad" Cholesterol, and How It May Impact the Risk of Heart Attack or StrokeThe Yankees, Red Sox, Phillies, Braves, Astros, Cardinals, Giants, Padres, and Angels are joining Merck to help educate fans about high bad cholesterol and how it may increase the risk of heart attack or stroke Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced a collaboration with nine professional baseball teams and former professional baseball players to launch the Playing with Heart educational program to help educate adults about the importance of knowing their low-density lipoprotein cholesterol (LDL-C), called "bad" cholesterol, number and the potential increased risk of heart attack or stroke. Playing with Heart connects Merck's commitment to
- PRMerck Announces Expiration of Hart-Scott-Rodino Act Waiting Period to Acquire Terns Pharmaceuticals, Inc.Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), in connection with Merck's pending acquisition of Terns Pharmaceuticals, Inc. ("Terns") (NASDAQ:TERN) expired at 11:59 p.m., Eastern Time, on April 23, 2026. As previously announced on April 7, 2026, Merck commenced, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Terns, for $53.00 net in cash for each share of Terns common stock validly tendered and not validly withdrawn in the offer, without interest and less any applicable tax withholding. The ex
- PRMerck and Google Cloud Partner to Accelerate Agentic AI Enterprise TransformationNew collaboration taps Gemini Enterprise to realize business-driving value, innovation and patient impact across the next era of biopharmaceutical growthLAS VEGAS, April 22, 2026 /PRNewswire/ -- Cloud Next '26 -- Merck (NYSE:MRK), known as MSD outside of the United States and Canada, and Google Cloud today announced a landmark partnership to enhance Merck's digital backbone as an AI-enabled enterprise. This multi-year investment, valued at up to $1 billion, will deploy an agentic platform across Merck's research & development (R&D), manufacturing, commercial, and corporate functions—and includes Google Cloud engineers working alongside Merck teams to deploy Google Cloud's most sophisticated
- PRFDA Approves Merck's Once-Daily IDVYNSO™ (doravirine/islatravir)IDVYNSO is approved for adults with virologically suppressed HIV-1 with no history of virologic treatment failure and no known substitutions associated with resistance to doravirine IDVYNSO is the first and only non-INSTI, tenofovir-free, once-daily, complete two-drug regimen to demonstrate non-inferior efficacy in a head-to-head Phase 3 trial versus three-drug regimen BIKTARVY®i (BIC/FTC/TAF) Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) approved IDVYNSO™, a new, two-drug single-tablet regimen of 100 mg doravirine and 0.25 mg islatravir, for the treatment of HIV-1 infection in adults to replace t
- PREuropean Commission Approves Merck's ENFLONSIA™ (clesrovimab) for the Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants During Their First RSV SeasonENFLONSIA is the first and only RSV preventive option in the European Union for administration to infants without the need for weight-based dosing Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced today that the European Commission (EC) has approved ENFLONSIA™ (clesrovimab) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates (newborns) and infants during their first RSV season. ENFLONSIA is contraindicated for infants with hypersensitivity to the active substance or any of its excipients. ENFLONSIA is a preventive, long-acting monoclonal antibody (mAb) designed to provide direct, rapid and durable protection
- PRNew Survey Shows HPV Awareness Isn't Keeping Pace with Certain HPV-Related Cancer Trends in CanadaKIRKLAND, QC, April 15, 2026 /CNW/ -- Merck (NYSE:MRK), known as MSD outside the United States and Canada, has released new data examining Canadians' knowledge of human papillomavirus (HPV) across age, gender, and regional groups. The survey revealed notable gaps in awareness—particularly among men and younger adults—even as rates of certain HPV‑related cancers continue to rise across the country. Key Survey Findings: Among younger adult respondents aged 18-24, fewer than half (49%) recognized HPV as a sexually transmitted infection, and about one‑third (34%) of the same group r
- PRIfinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer who Experienced Disease Progression on or After Platinum-Based ChemotherapyBased on results from IDeate-Lung01 Phase 2 trial, with support from IDeate-PanTumor01 Phase 1/2 trial If approved, ifinatamab deruxtecan would be a first-in-class B7-H3 directed DXd antibody drug conjugate for these patients Daiichi Sankyo (TSE: 4568) and Merck's (NYSE:MRK), known as MSD outside of the United States and Canada, Biologics License Application (BLA) for ifinatamab deruxtecan (I-DXd) has been accepted and granted Priority Review by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy. The Prescription Drug User Fee Act (PDUFA) d
- SECSEC Form DEFA14A filed by Merck & Company Inc.DEFA14A - Merck & Co., Inc. (0000310158) (Filer)
- SECSEC Form DEF 14A filed by Merck & Company Inc.DEF 14A - Merck & Co., Inc. (0000310158) (Filer)
- PRMerck Begins Tender Offer to Acquire Terns Pharmaceuticals, Inc.Merck (NYSE:MRK), known as MSD outside of the United States and Canada, is commencing today, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Terns Pharmaceuticals, Inc. ("Terns") (NASDAQ:TERN). On March 25, 2026, Merck announced that it had entered into a definitive agreement to acquire Terns. Upon the successful closing of the tender offer, stockholders of Terns will receive $53.00 net in cash for each share of Terns common stock validly tendered and not validly withdrawn in the offer, without interest and less any applicable tax withholding. Following the purchase of shares in the tender offer, Terns will become a wholly owned subsidiary o
- PRMerck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus), an Investigational Bispecific Tie2 Agonist/VEGF Inhibitor, for the Treatment of Neovascular Age-Related Macular DegenerationMerck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the initiation of a pivotal Phase 2b/3 trial evaluating MK-8748 (also known as Tiespectus, EYE201), a novel investigational bispecific antibody that directly activates Tie2 signaling and inhibits vascular endothelial growth factor (VEGF), for the treatment of neovascular (wet) age-related macular degeneration (NVAMD). The study, known as MALBEC, is the first trial of a broader late-phase development program for MK-8748, with a second study in NVAMD scheduled to begin this year (NCT07496567). The decision to advance into pivotal studies is based on results from the Phase 1/2a RIOJA trial (NCT06664502),
- PREuropean Commission Approves KEYTRUDA® (pembrolizumab) Plus Paclitaxel ± Bevacizumab for the Treatment of Adults With PD-L1 (CPS ≥1) Platinum-Resistant Recurrent Ovarian Carcinoma Who Have Received One or Two Prior Systemic Treatment RegimensThe KEYTRUDA regimen is the first and only PD-1 inhibitor-based treatment approved in the European Union for these patients Approval supported by data from the Phase 3 KEYNOTE-B96 trial in which the KEYTRUDA regimen demonstrated a statistically significant improvement in progression-free and overall survival compared to placebo plus paclitaxel, with or without bevacizumab Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced that KEYTRUDA® (pembrolizumab), in combination with paclitaxel, with or without bevacizumab, is approved in the European Union (EU) for the treatment of platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal carcinoma
- INSIDERSEC Form 4 filed by Seidman Christine E4 - Merck & Co., Inc. (0000310158) (Issuer)
- INSIDERSEC Form 4 filed by Glocer Thomas H4 - Merck & Co., Inc. (0000310158) (Issuer)
- INSIDERSEC Form 4 filed by Coe Mary Ellen4 - Merck & Co., Inc. (0000310158) (Issuer)
- PRMerck to Hold First-Quarter 2026 Sales and Earnings Conference Call April 30Merck (NYSE:MRK), known as MSD outside of the United States and Canada, will hold its first-quarter 2026 sales and earnings conference call with institutional investors and analysts at 9:00 a.m. ET on Thursday, April 30. During the call, company executives will provide an overview of Merck's performance for the quarter. Investors, journalists and the general public may access a live audio webcast of the call via this weblink. A replay of the webcast, along with the sales and earnings news release, supplemental financial disclosures and slides highlighting the results, will be available at www.merck.com. All participants may join the call by dialing (800) 369-3351 (U.S. and Canada Toll-F
- PRMerck's Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Demonstrated Significantly Greater LDL-C Reductions at Eight Weeks Compared to Guideline-Recommended Oral Non-Statin Therapies When Added to Background StatinsThe Phase 3 CORALreef AddOn trial compared the efficacy and safety of enlicitide to bempedoic acid, ezetimibe or bempedoic acid with ezetimibe Enlicitide has the potential to be the first approved oral PCSK9 inhibitor designed to help address critical unmet needs for patients with hypercholesterolemia and help combat the ongoing cardiovascular (CV) epidemic Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced detailed results from CORALreef AddOn, an active comparator study designed to evaluate the efficacy and safety of enlicitide decanoate compared to other oral non-statin therapies (bempedoic acid, ezetimibe or bempedoic acid with ezetimibe) when ad
- PRPositive Data from Phase 2 CADENCE Trial Provides Definitive Proof-of-Concept for WINREVAIR™ (sotatercept-csrk) in Adults With the Syndrome of Combined Post- and Precapillary Pulmonary Hypertension and Heart Failure With Preserved Ejection FractionMerck's WINREVAIR met primary endpoint of change in pulmonary vascular resistance (PVR), significantly improving the ability of blood to flow through the lungs to the heart Totality of evidence across hemodynamic, functional, echocardiographic and clinical endpoints supports advancing development of WINREVAIR for this distinct patient population into a registrational Phase 3 study Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced detailed results from the Phase 2 CADENCE study, which was designed to evaluate the efficacy, safety and tolerability of two doses (0.3 mg/kg and 0.7 mg/kg) of WINREVAIR™ (sotatercept-csrk) for the treatment of adults with
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Merck & Company Inc.SCHEDULE 13G/A - Merck & Co., Inc. (0000310158) (Subject)
- PRMerck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)Terns' lead candidate TERN-701 is an investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor currently in Phase 1/2 development for certain patients with CML Merck to hold investor call at 8 a.m. EDT today RAHWAY, N.J. and FOSTER CITY, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Merck (NYSE:MRK), known as MSD outside of the United States and Canada, and Terns Pharmaceuticals, Inc. ("Terns") (NASDAQ:TERN), a clinical-stage oncology company, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Terns for $53.00 per share in cash for an approximate equity value of $6.7 billion. This equates to approximate
- PRMerck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)Terns' lead candidate TERN-701 is an investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor currently in Phase 1/2 development for certain patients with CML Merck to hold investor call at 8 a.m. EDT today Merck (NYSE:MRK), known as MSD outside of the United States and Canada, and Terns Pharmaceuticals, Inc. ("Terns") (NASDAQ:TERN), a clinical-stage oncology company, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Terns for $53.00 per share in cash for an approximate equity value of $6.7 billion. This equates to approximately $5.7 billion net of acquired cash and represents an approximate premi
- PRNew Public Listings for Canadians Living with Pulmonary Arterial HypertensionKIRKLAND, QC, March 24, 2026 /CNW/ -- Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced today that British Columbia, Non-Insured Health Benefits (NIHB), Nova Scotia, Quebec and Veterans Affairs Canada (VAC) have added WINREVAIR® (sotatercept) to their public drug formularies. As the first jurisdictions to implement public coverage following the completed pan-Canadian Pharmaceutical Alliance (pCPA) agreement, these listings mark an important step toward improving access for Canadians living with pulmonary arterial hypertension (PAH), a rare, progressive and life‑limiting disease.
- PRFDA Approves BRAVECTO® QUANTUM (fluralaner for extended-release injectable suspension) from Merck Animal Health to Treat and Control Asian Longhorned Tick and Gulf Coast Tick for 12 Months in DogsExpanded label for once-yearly parasiticide treatment for dogs now includes Haemaphysalis longicornis (Asian longhorned tick) and Amblyomma maculatum (Gulf Coast tick) for 12 months Merck Animal Health, known as MSD Animal Health outside the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced the U.S. Food and Drug Administration (FDA) approved an expanded label for BRAVECTO® QUANTUM (fluralaner for extended-release injectable suspension) in dogs. The updated indication adds treatment and control of Asian longhorned tick (H. longicornis) and Gulf Coast tick (A. maculatum) for 12 months, when administered as a single, veterinarian‑delive
MRK FAQ
6 questionsWhat does Merck & Company Inc. do?
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected...Where does MRK stock trade?
Merck & Company Inc. (MRK) is listed on NYSE.What sector and industry is MRK in?
Merck & Company Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about MRK?
Merck & Company Inc. has had 8 recent analyst actions on file. The most recent action was from RBC Capital Mkts: Outperform on 2026-02-25.What companies are similar to MRK?
Notable peers in the same industry include AZN (AstraZeneca PLC), NVS (Novartis AG), AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), PFE (Pfizer Inc.). Compare MRK side-by-side with any of them on Quantisnow.How can I track MRK on Quantisnow?
Quantisnow aggregates Merck & Company Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MRK to receive live email and push alerts on every new disclosure.